Sandwich vs Competitive Assays: Format Selection & Reagent Strategy

Introduction

Sandwich and competitive assays are two of the most widely used immunoassay formats across both ELISA and lateral flow. They are often introduced as a simple choice based on analyte size, with sandwich assays generally suited to larger targets and competitive assays more often used for smaller molecules. In practice, however, format choice influences far more than target fit alone.

The assay format shapes specificity, sensitivity, ease of interpretation, optimisation strategy and how readily an assay can be translated into a robust and reproducible product. Format choice also influences the balance of considerations during development. In sandwich assays, this often includes antibody pair selection, epitope accessibility and the performance of the capture & detector reagents in the final format. In competitive assays, it more often includes the design and presentation of the competing reagent, together with the consistency of the coated and conjugated components that shape the assay response. These considerations also need to be viewed in the context of the intended assay platform, whether the development work is focused on ELISA or lateral flow.

Alongside this, reagent quality and consistency often play a larger role than is first assumed. A format that appears straightforward at proof-of-concept stage may become more complex once real samples, material selection and lot-to-lot variation are taken into account. Equally, a format that looks more demanding on paper may prove to be the better route if the underlying reagents can be controlled more effectively.

This article looks at sandwich and competitive assays from that broader assay development perspective, focusing on format choice, key considerations across ELISA & lateral flow and the reagent strategy needed to support robust assay performance.

Sandwich vs Competitive Assays: Key Format Differences

Sandwich Assays

A sandwich assay is generally the preferred option when the analyte can support dual recognition. In this format, the target is captured by one binding reagent and detected by a second, effectively forming a sandwich around the analyte. This usually requires a target with more than one accessible epitope, which is why sandwich assays are most commonly used for larger analytes such as proteins, including biomarkers, antigens and enzymes.

One of the main strengths of the sandwich format is specificity. The use of two recognition events can improve selectivity, and the signal is usually intuitive, with increasing analyte concentration leading to increasing signal. In both ELISA and lateral flow, this can make sandwich assays comparatively straightforward to interpret. When a strong matched pair is available, the format can also support very good analytical performance.

The main consideration is the antibody pair itself. It is not enough for two antibodies to bind the same target independently. They must bind distinct, non-overlapping sites and continue to perform when one is immobilised and the other is labelled. Pair performance may also depend on the final assay conditions, so early promise does not always translate directly into a robust final assay. One antibody may perform well when immobilised as the capture reagent but less well when used as the labelled detector, or vice versa.

Competitive Assays

Competitive assays become necessary when the analyte cannot support a classical sandwich design. This is typically the case for small molecules, haptens and other low molecular weight targets. In this context, a hapten is a small molecule that is too small to support a classical sandwich assay and is therefore often used in competitive assay formats. Examples include food toxins, drugs of abuse and small molecule hormones or hormone metabolites.

Competitive assays differ from sandwich assays in both signal logic and development focus. Rather than increasing signal with increasing analyte concentration, competitive formats usually show the opposite relationship, with higher analyte concentration resulting in a weaker test signal. However, this inverse signal format can be less intuitive to interpret, particularly in visually read assays.

Competitive assays are therefore well suited to targets that cannot be measured using a classical sandwich format. However, that does not necessarily make them simpler to develop, as assay performance often depends heavily on analogue design, conjugation strategy and the consistency of the reagents that drive the competitive interaction. Specificity can also be particularly challenging in competitive assays, as the antibody often has to discriminate between closely related compounds with only small structural differences.

Two Common Competitive Arrangements

Although “competitive assay” is often used as a broad term for both formats, it is useful here to distinguish between Inhibition-style and Competitive-style arrangements because the assay architecture and development considerations are not identical. In this article, inhibition-style refers to formats in which sample analyte inhibits binding of a labelled antibody to an immobilised analogue, whereas competitive-style refers to formats in which sample analyte competes with a labelled analogue for binding to an immobilised antibody.

As shown in the diagram below, two common competitive arrangements are used in assay development. In one, the test line or solid phase contains the analyte analogue, often presented as a hapten:protein conjugate, while the signal generating label carries the antibody. In this format, analyte in the sample inhibits binding of the labelled antibody to the immobilised hapten. In the other arrangement, the test line or solid phase carries the antibody, while the detector reagent is the labelled analyte analogue. Here, analyte in the sample competes with the labelled analogue for binding to the immobilised antibody.

Both arrangements produce the same broad outcome, with higher analyte concentration leading to a weaker signal. However, the balance of optimisation can differ between them. In formats where the analogue is immobilised, assay performance can be particularly sensitive to the quality, presentation and consistency of the coated conjugate. In formats where the labelled analogue is in the liquid phase, greater emphasis may fall on the design and behaviour of the tracer conjugate.

Development Considerations Across ELISA and Lateral Flow

Sandwich Formats

In sandwich assays, the main development consideration is the antibody pair. The capture and detector antibodies must recognise distinct, non-overlapping epitopes and perform well in their assigned roles.

In ELISA, this is often more straightforward to assess because capture, detection, incubation and washing can all be controlled closely. This makes pair screening, detector optimisation and background assessment more manageable during early development.

In lateral flow, the same pair must work within the final strip architecture, where flow, membrane interactions, conjugate release and line capture all affect assay behaviour. A pair that looks strong in ELISA may therefore require further optimisation in lateral flow, not because the recognition is wrong, but because the final format places different demands on how quickly and efficiently those interactions occur. Sandwich assays are generally easier to interpret than competitive formats, but they still depend heavily on selecting a pair that remains robust in the final assay system.

One further consideration in sandwich assays is susceptibility to certain immunoassay interferences. Heterophilic antibodies, including Human Anti-Mouse Antibodies (HAMA) and related anti-animal interferences, are classically associated with sandwich formats because they can bridge the capture and detector system and generate false signal. The exact risk depends on the antibody system used, but it remains an important consideration during assay design.

Inhibition-Style Formats

In inhibition-style formats, the sample analyte binds the labelled antibody and inhibits its binding to an immobilised analogue. In ELISA, this is often implemented by coating the solid phase with the analogue, commonly as a hapten:protein conjugate and then detecting bound primary antibody directly or indirectly. This can be a practical format where multiple assays are built around different antisera but a common secondary detection system is used, since the same labelled secondary reagent can support multiple assays. It can also be more forgiving from a chemistry perspective, because the coated carrier does not need to retain reporter activity.

For ELISA, the main development levers usually sit with the coated analogue. The amount coated, the way the hapten is presented and the degree of incorporation can all influence assay response. More coating or higher incorporation may increase baseline signal, but may also make the inhibition harder to achieve, which can reduce sensitivity. For small molecule targets, coupling the analogue to a carrier protein is often important not only for immunogen design, but also for solid phase presentation, since the free hapten alone may be too small to immobilise on the plate.

In lateral flow, the same broad format is often attractive because antibody conjugation to nanoparticles is relatively well established, while the analogue can be optimised separately as a coated test line reagent. This arrangement may also offer a kinetic advantage in some systems, because the analyte can begin interacting with the labelled antibody before the complex reaches the test line. That distinction is usually less important in ELISA, where longer incubation times allow the interaction to develop more fully.

For lateral flow, the coated test line reagent often becomes one of the main determinants of assay performance. The analogue must be presented strongly enough to give a clear line, but not so strongly that inhibition becomes difficult within the required assay range. In practice, inhibition-style formats in both ELISA and lateral flow tend to place most emphasis on the design, presentation and loading of the coated analogue.

Competitive-Style Formats

In competitive-style formats, the sample analyte competes with a labelled analogue for binding to an immobilised antibody. In ELISA, this is typically achieved by coating the plate with antibody and using a directly labelled analogue, for example an enzyme-labelled analyte analogue, as the competing reagent. This can give a simpler assay architecture by removing the need for a secondary detection step, provided a suitable labelled analogue is available.

The main ELISA considerations in this format usually centre on the labelled analogue itself. It must retain antibody recognition while also remaining compatible with the reporter. For some targets, such as short peptide haptens, this may be relatively straightforward. For very small molecules, however, direct labelling can be more demanding. The analogue may be more difficult to prepare, control and purify from unconjugated material, particularly where the size or physicochemical difference between conjugated and unconjugated species is limited. In those cases, reaction stoichiometry and purification strategy become important parts of development.

In lateral flow, the same format places the labelled analogue on the nanoparticle and the antibody at the test line. The assay logic is similar, but the practical burden can be greater because the competing analogue now has to function as part of the nanoparticle conjugate rather than as a coated reagent. This can require more optimisation than a conventional antibody-particle conjugate, particularly for very small analytes.

One reason for this is that analogue presentation at the particle surface can be sensitive to both conjugation conditions and colloid stabilisation. Blocking agents used to stabilise the particle, such as BSA on gold nanoparticles, may also crowd or partially mask the small analogue, reducing its accessibility. For that reason, competitive-style formats in both ELISA and lateral flow tend to place more emphasis on the labelled analogue, but this becomes especially important in lateral flow, where the analogue must function within the final nanoparticle conjugate as well as within the assay itself.

Reagent and Conjugation Considerations

Hapten:Protein Conjugates

For many competitive assays, hapten:protein conjugates are central reagents. They may be used as coated materials on the test line or as labelled analogues within the assay itself. A hapten:BSA conjugate is a common example, but not all such conjugates behave equally well in an assay context. For small-molecule targets, related hapten:carrier conjugates may also be needed earlier in development to generate the antibody response, for example by coupling the hapten to a carrier such as KLH during immunisation.

The carrier protein, the site of attachment and the overall presentation of the hapten can all influence recognition. A conjugate that is chemically acceptable may still perform poorly if the hapten is not presented in a way that supports the desired assay response. This is particularly important when the same small-molecule target may need to be recognised consistently across different reagent lots and development stages.

Conjugation Chemistry and Linker Design

The chemistry used to prepare a hapten:protein conjugate directly affects how the hapten is presented to the antibody. Depending on the hapten and carrier, conjugation may make use of available amine, carboxyl, hydroxyl or sulfhydryl chemistry. The choice of coupling group determines where the hapten is attached, which in turn influences whether the recognised part of the molecule remains accessible after conjugation. If the hapten is coupled through or close to the key recognition site, antibody binding can be reduced or lost.

Linker design also plays a practical role. Introducing a spacer can improve binding by projecting the hapten away from the carrier surface, but it can also change how the antibody “sees” the target if it alters orientation or local environment. In practice, the combination of coupling site and linker defines how the hapten is displayed, and this can have a direct impact on assay response.

Different conjugation approaches can therefore produce conjugates with the same nominal composition but different assay behaviour. For that reason, conjugation chemistry is part of assay optimisation, not just reagent preparation.

Incorporation and Characterisation

The degree of hapten incorporation onto the carrier protein is another important consideration. Overloaded conjugates can lead to distorted presentation, altered binding behaviour or a compressed competition window. Under-loaded conjugates may result in weak capture or insufficient signal. In practice, incorporation level is often adjusted during development to achieve the desired balance between signal strength and inhibition behaviour, rather than being treated as a fixed property of the conjugate.

For hapten:protein conjugates, incorporation can be assessed using methods suited to the chemistry used, including depletion assays for reactive groups such as TNBS, mass-based approaches and hapten-specific analytical techniques used to support conjugation & purity assessment. The aim is to quantify how much hapten is attached and relate that to assay performance, rather than relying on nominal reaction conditions alone.

Off-the-Shelf vs Assay-Optimised Reagents

Off-the-shelf reagents can be useful starting materials, but they are not always matched to the needs of a specific assay. A commercial hapten:protein conjugate may perform adequately in ELISA, but not necessarily in lateral flow, where line intensity, signal window and presentation can be more sensitive to incorporation level and conjugate design.

Another practical consideration is consistency. Differences in conjugation level or preparation between lots can lead to measurable shifts in assay response, particularly in competitive formats where the analogue plays a direct role in defining signal.

This becomes more important as development progresses. A reagent that is acceptable for initial screening may not provide the control needed for optimisation and scale-up. For that reason, characterisation of conjugation level and purity is typically used alongside assay data to select and control reagents that are suitable for continued development.

Conclusion

Sandwich and competitive formats each have clear strengths, the most suitable choice depends on the target and the intended application. Sandwich assays remain the natural choice where the analyte supports dual recognition, offering strong specificity and a more intuitive signal. Competitive assays are required for many small-molecule targets, including toxins, drugs of abuse and hormone related analytes.

In practice, the most useful question is not simply whether an assay is sandwich or competitive, but how well that format fits the analyte, the platform and the supporting reagent strategy. For sandwich assays, this often centres on the quality and compatibility of the antibody pair. For competitive assays, it depends just as strongly on selecting the right analogue format, presenting that analogue effectively and controlling the coated or labelled reagent closely enough to deliver the required assay response. For many small molecule assays, this makes reagent chemistry a central part of assay design.

Carrier selection, functional group choice, linker design, incorporation level and conjugate characterisation all influence how reliably that assay response can be achieved and maintained. When these are considered from the outset, they provide a stronger foundation for assay development in both ELISA and lateral flow.

Learn more about our Immunoassay Development, Lateral Flow Assay Development and Bioconjugation Services. Contact us to discuss your project and explore how we can support your assay development goals.

Get in Touch